IRIS PubliCatt

Richeldi, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.929
EU - Europa 2.927
AS - Asia 743
AF - Africa 64
OC - Oceania 31
SA - Sud America 29
Continente sconosciuto - Info sul continente non disponibili 9
Totale 7.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.874
SE - Svezia 803
IT - Italia 762
PL - Polonia 381
CN - Cina 336
IE - Irlanda 293
GB - Regno Unito 163
FR - Francia 157
DE - Germania 144
IN - India 102
BE - Belgio 40
IR - Iran 38
UA - Ucraina 37
CA - Canada 36
HK - Hong Kong 34
VN - Vietnam 34
FI - Finlandia 32
JP - Giappone 31
AU - Australia 25
CH - Svizzera 24
KR - Corea 23
CI - Costa d'Avorio 22
SA - Arabia Saudita 22
NL - Olanda 16
RU - Federazione Russa 16
PH - Filippine 14
SG - Singapore 14
TR - Turchia 13
EG - Egitto 12
PK - Pakistan 12
BR - Brasile 11
CO - Colombia 11
CZ - Repubblica Ceca 11
MX - Messico 11
MY - Malesia 11
TW - Taiwan 11
RO - Romania 9
AE - Emirati Arabi Uniti 8
EU - Europa 8
GR - Grecia 7
BD - Bangladesh 6
NZ - Nuova Zelanda 6
PT - Portogallo 6
TN - Tunisia 6
AT - Austria 5
BZ - Belize 5
DK - Danimarca 5
IL - Israele 5
NG - Nigeria 5
SD - Sudan 5
ZA - Sudafrica 5
IQ - Iraq 4
KZ - Kazakistan 4
MD - Moldavia 4
NP - Nepal 4
PE - Perù 4
TH - Thailandia 4
JO - Giordania 3
MA - Marocco 3
NO - Norvegia 3
BT - Bhutan 2
CM - Camerun 2
EC - Ecuador 2
ES - Italia 2
HR - Croazia 2
HU - Ungheria 2
KE - Kenya 2
MG - Madagascar 2
MO - Macao, regione amministrativa speciale della Cina 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
CL - Cile 1
EE - Estonia 1
GE - Georgia 1
ID - Indonesia 1
KW - Kuwait 1
LK - Sri Lanka 1
LT - Lituania 1
ME - Montenegro 1
MM - Myanmar 1
PA - Panama 1
PR - Porto Rico 1
TT - Trinidad e Tobago 1
Totale 7.732
Salva come PNG Salva come JPEG
Città #
Chandler 665
Warsaw 377
Ashburn 358
Fairfield 330
Dublin 292
Wilmington 189
Beijing 180
Rome 159
Woodbridge 156
Milan 153
Princeton 147
San Mateo 136
Houston 132
Seattle 130
Boston 122
Ann Arbor 104
New York 97
Cambridge 94
Chicago 79
Jacksonville 41
Bremen 35
Marseille 35
London 32
Augusta 30
Brussels 30
Dearborn 28
Los Angeles 28
Redwood City 28
Dong Ket 26
Helsinki 25
Kish 25
Nanjing 24
Cattolica 23
Washington 23
Abidjan 22
Trieste 21
Boardman 19
Norwalk 19
Pune 19
Hong Kong 16
Kunming 16
San Diego 16
Dammam 12
Hangzhou 12
Nanchang 12
Tokyo 12
Andover 11
Chiswick 11
Columbus 11
Oggiono 11
Zurich 11
Bern 10
Busto Arsizio 10
Leawood 10
Brno 9
Central 9
Changsha 9
Fremont 9
Millbury 9
Naples 9
Shanghai 9
Turin 9
Monterrey 8
Monza 8
Redmond 8
Sydney 8
Taipei 8
Toronto 8
Al Qatif 7
Chita 7
Frankfurt am Main 7
Lappeenranta 7
Singapore 7
Bergamo 6
Cairo 6
Guangzhou 6
Hyderabad 6
Seoul 6
Thessaloniki 6
Zhengzhou 6
Belize City 5
Boydton 5
Buffalo 5
Cape Town 5
Edinburgh 5
Falls Church 5
Ferrara 5
Florence 5
Istanbul 5
Lahore 5
Monmouth Junction 5
Mountain View 5
Mumbai 5
Munich 5
San Jose 5
St Louis 5
Swansea 5
Tianjin 5
Tienen 5
Vicenza 5
Totale 4.911
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 411
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. 359
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 160
Subclinical interstitial lung abnormalities: Lumping and splitting revisited 153
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials 141
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis 138
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 124
Assessment of neurological manifestations in hospitalized patients with COVID-19 108
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 107
Reply to Moodley and to Ravaglia et al 101
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 98
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 97
Idiopathic Pulmonary Fibrosis: State of the Art for 2023 91
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials 89
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis 89
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 87
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 85
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study 82
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 71
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 70
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 69
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 69
Sarilumab use in severe SARS-CoV-2 pneumonia 68
A real-time integrated framework to support clinical decision making for covid-19 patients 68
COVID-19 and interstitial lung disease: Keep them separate 66
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society 65
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 65
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia 63
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 62
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis 62
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 61
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 60
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 60
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 59
Residual respiratory impairment after COVID-19 pneumonia 59
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue 57
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 56
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) 55
Idiopathic pulmonary fibrosis 54
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper 54
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 54
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 53
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 52
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: Preliminary results 52
Severe asthma: One disease and multiple definitions 52
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 51
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 51
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 51
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis 49
Treatment strategies for asthma: Reshaping the concept of asthma management 49
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry 49
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective 49
Antibody-based therapies for idiopathic pulmonary fibrosis 48
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study 47
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy 47
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings 47
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial 46
Statin therapy and lung disorders 46
New frontiers in ultrasonography of the mediastinum: Pediatric EBUS-TBNA 46
Determinants and Evolution of Obstructive Sleep Apnea Syndrome After Myocardial Infarction 46
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 46
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 46
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 46
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study 46
The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: Surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory 45
Current and Future Idiopathic Pulmonary Fibrosis Therapy 45
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations 45
Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis 44
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 44
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 44
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 42
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 42
Current Diagnosis and Management of Hypersensitivity Pneumonitis 41
Do randomized clinical trials always provide certain results? 40
Reply to: Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj 40
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease 40
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data 39
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? 39
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey 39
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 38
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis 38
Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis 38
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 37
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 36
Residual respiratory impairment after COVID-19 pneumonia 35
Contemporary Concise Review 2018: Interstitial lung disease 35
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis 35
The impact of fixed triple therapy with beclometasone/formoterol/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease (COPD) in an italian context of real life: The TRITRIAL study protocol 35
Antibody-based therapies for idiopathic pulmonary fibrosis 34
Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: What an Indian female patient tells us 34
Post-COVID lung fibrosis: The tsunami that will follow the earthquake 34
Advances with pharmacotherapy for the treatment of interstitial lung disease 34
Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline 33
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 33
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management 33
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions 32
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis 32
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement 32
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 31
CC-90001, a c-Jun N-Terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: Design of a phase 2, randomised, placebo-controlled trial 31
Totale 6.411
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.739
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194 0 0 0 0 0 0 0 0 0 0 3 1
2019/2020717 20 68 12 29 14 19 25 5 152 113 194 66
2020/20211.449 52 112 117 99 137 116 256 199 88 133 68 72
2021/20221.487 139 75 29 154 55 47 30 237 61 64 335 261
2022/20232.868 310 294 269 420 269 351 131 175 306 145 124 74
2023/20241.429 68 430 90 96 99 203 132 72 88 142 9 0
Totale 8.023